Article
Chemistry, Medicinal
Reinier Cardentey Sanchez, Amado Diaz de la Fe, Alejandro Pelaez Suarez, Dayme Grass, Teresa Morgado Vega, Armando Sanchez Canal, Dario Siniscalco, Maria de los Angeles Robinson Agramonte
Summary: Multiple sclerosis is an autoimmune neurodegenerative disease that lacks a curative treatment. The use of interferon beta 1a has shown safety and efficacy in treating relapsing remitting MS patients, with significant reductions in attacks, disability scale scores, and lesions observed.
DRUG DEVELOPMENT RESEARCH
(2021)
Article
Biology
Cristina-Florentina Plesa, Diana Maria Chitimus, Carmen Adella Sirbu, Monica Marilena Tantu, Minerva Claudia Ghinescu, Daniela Anghel, Florentina Ionita-Radu
Summary: This case study describes a particular association between the remission phase of multiple sclerosis and the violent onset of interferon-induced thrombotic thrombocytopenic purpura.
Review
Pharmacology & Pharmacy
Yahiya Y. Syed
Summary: Alemtuzumab is an effective treatment option for patients with highly active RRMS, with maintained treatment benefits over up to 9 years. It has an acceptable tolerability profile and convenient treatment regimen.
Article
Neurosciences
Jianfeng Bao, Hui Tu, Yijia Li, Jubao Sun, Zhigang Hu, Fengshou Zhang, Jinghua Li
Summary: Our study revealed widespread microstructure changes in normal-appearing white matter (NAWM) in relapsing-remitting multiple sclerosis (RRMS) patients through a ready-made white matter atlas and probabilistic lesion map. These findings support the hypothesis of demyelination, accumulation of inflammatory cells, and axonal injury in NAWM for RRMS. The DTI-based metrics could be considered as potential non-invasive biomarkers of disease severity.
FRONTIERS IN NEUROSCIENCE
(2022)
Article
Clinical Neurology
Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke Van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad, Raed Alroughani, Raymond Hupperts, Murat Terzi, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Vincent Van Pesch, Franco Granella, Roberto Bergamaschi, Daniele Spitaleri, Mark Slee, Steve Vucic, Radek Ampapa, Pamela McCombe, Cristina Ramo-Tello, Julie Prevost, Javier Olascoaga, Edgardo Cristiano, Michael Barnett, Maria Laura Saladino, Jose Luis Sanchez-Menoyo, Suzanne Hodgkinson, Csilla Rozsa, Stella Hughes, Fraser Moore, Cameron Shaw, Ernest Butler, Olga Skibina, Orla Gray, Allan Kermode, Tunde Csepany, Bhim Singhal, Neil Shuey, Imre Piroska, Bruce Taylor, Magdolna Simo, Carmen-Adella Sirbu, Attila Sas, Helmut Butzkueven
Summary: The study demonstrates that continued treatment with MS immunotherapies significantly reduces disability accrual, risk of needing a walking aid, and frequency of relapses over a 15-year period.
Article
Clinical Neurology
Anthony T. Reder, Nancy Arndt, Cortnee Roman, Caroline Geremakis, Jason P. Mendoza, Ray Su, Charles Makin, Robin L. Avila, Megan C. Vignos
Summary: In this study, peginterferon beta-1a was found to be associated with lower annualized relapse rates compared to glatiramer acetate or teriflunomide in RRMS patients, while no significant difference in relapse rates was observed when compared to SC IFN beta-1a. Other measured secondary outcomes also did not show significant differences between the treatment cohorts.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Neurosciences
Yasuyuki Kihara, Yunjiao Zhu, Deepa Jonnalagadda, William Romanow, Carter Palmer, Benjamin Siddoway, Richard Rivera, Ranjan Dutta, Bruce D. Trapp, Jerold Chun
Summary: This study used snRNA-seq to analyze 33,197 nuclei from 8 normal-appearing MS brains, revealing cell type-specific changes between RRMS and SPMS. Interestingly, the downregulation of astrocytic sphingosine kinases in SPMS brains could affect the activity of the MS drug fingolimod. These findings provide an initial resource for studying non-lesioned RRMS and SPMS brain cell units.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2022)
Article
Neuroimaging
Shannon Kolind, Shawna Abel, Carolyn Taylor, Roger Tam, Cornelia Laule, David K. B. Li, Hideki Garren, Laura Gaetano, Corrado Bernasconi, David Clayton, Irene Vavasour, Anthony Traboulsee
Summary: Ocrelizumab appears to protect against demyelination in multiple sclerosis patients and may provide a more favorable environment for remyelination.
NEUROIMAGE-CLINICAL
(2022)
Review
Clinical Neurology
Leorah Freeman, Erin E. Longbrake, Patricia K. Coyle, Barry Hendin, Timothy Vollmer
Summary: Disease-modifying therapies for multiple sclerosis can help change the course of the disease, with the debate centering around the selection of treatments for newly diagnosed patients. Early use of high-efficacy therapies (HETs) may reduce neurological damage and enhance long-term clinical outcomes for patients.
Article
Clinical Neurology
J. William L. Brown, Nick G. Cunniffe, Ferran Prados, Baris Kanber, Joanne L. Jones, Edward Needham, Zoya Georgieva, David Rog, Owen R. Pearson, James Overell, David MacManus, Rebecca S. Samson, Jonathan Stutters, Charles Ffrench-Constant, Claudia A. M. Gandini Wheeler-Kingshott, Carla Moran, Paul D. Flynn, Andrew W. Michell, Robin J. M. Franklin, Siddharthan Chandran, Daniel R. Altmann, Declan T. Chard, Peter Connick, Alasdair J. Coles
Summary: This study aimed to evaluate the safety and efficacy of non-selective retinoid X receptor agonist bexarotene in promoting remyelination in patients with multiple sclerosis. The results showed that the bexarotene treatment group had more adverse events and poor efficacy outcome, therefore not recommended for the treatment of multiple sclerosis.
Article
Clinical Neurology
Martin Valis, Zbysek Pavelek, Michal Novotny, Blanka Klimova, Jana Sarlakova, Simona Haluskova, Marek Peterka, Ivana Stetkarova, Pavel Stourac, Jan Mares, Pavel Hradilek, Radek Ampapa, Marta Vachova, Eva Recmanova, Eva Meluzinova
Summary: This study analyzed the characteristics and treatment of pediatric patients with multiple sclerosis. The results showed that these patients usually start disease-modifying drug treatment at the age of 15.89, with moderate and mild relapses being common. Moreover, the first-choice treatment is similar to that of adult patients, but low efficacy or lack of tolerance may lead to treatment discontinuation in children.
FRONTIERS IN NEUROLOGY
(2022)
Article
Neuroimaging
Elizabeth N. York, Rozanna Meijboom, Michael J. Thrippleton, Mark E. Bastin, Agniete Kampaite, Nicole White, Siddharthan Chandran, Adam D. Waldman, FutureMS Consortium
Summary: In recently diagnosed RRMS patients, g-ratio and ICVF increased in NAWM, while MTsat, NODDI ICVF, and ISOVF increased in WML over time. Longitudinal changes in microstructural measures are significant at a group level, but limited by technique reproducibility in individual patients with early RRMS.
NEUROIMAGE-CLINICAL
(2022)
Review
Clinical Neurology
Marco Biolato, Assunta Bianco, Matteo Lucchini, Antonio Gasbarrini, Massimiliano Mirabella, Antonio Grieco
Summary: This review analyzed data on hepatotoxicity of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis, finding that while serious liver adverse events are rare, the exact incidence is unknown, and all current DMTs for multiple sclerosis have potential hepatic toxic effects.
Article
Clinical Neurology
John F. Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, Karen Smirnakis, Shan Xiao, George Kong, Robert Kuhelj, Nolan Campbell
Summary: This study aimed to assess the safety and efficacy of natalizumab dosing once every 6 weeks compared to once every 4 weeks in patients with relapsing-remitting multiple sclerosis. The results showed a numerical difference in the number of new or newly enlarging T2 hyperintense lesions at week 72 between the two dosing regimens, which reached statistical significance under the secondary estimand. The safety profiles of natalizumab dosing once every 6 weeks and once every 4 weeks were similar.
Article
Clinical Neurology
Bruce A. C. Cree, Myla D. Goldman, John R. Corboy, Barry A. Singer, Edward J. Fox, Douglas L. Arnold, Corey Ford, Bianca Weinstock-Guttman, Amit Bar-Or, Susanne Mientus, Daniel Sienkiewicz, Ying Zhang, Rajesh Karan, Nadia Tenenbaum
Summary: The study showed that fingolimod 0.5 mg had superior efficacy compared to glatiramer acetate 20 mg in treating patients with relapsing-remitting multiple sclerosis, with a consistent safety profile. Lower doses of fingolimod were not investigated, leaving their efficacy and safety risks unknown.
Article
Clinical Neurology
Cristina M. Gaudioso, Soe Mar, T. Charles Casper, Rachel Codden, Adam Nguyen, Gregory Aaen, Leslie Benson, Tanuja Chitnis, Carla Francisco, Mark P. Gorman, Manu S. Goyal, Jennifer Graves, Benjamin M. Greenberg, Janace Hart, Lauren Krupp, Timothy Lotze, Sona Narula, Sean J. Pittock, Mary Rensel, Moses Rodriguez, John Rose, Teri Schreiner, Jan-Mendelt Tillema, Amy Waldman, Bianca Weinstock-Guttman, Yolanda Wheeler, Emmanuelle Waubant, Eoin P. Flanagan
Summary: This study aims to determine the frequency of MOG-IgG and AQP4-IgG in pediatric-onset multiple sclerosis (POMS) patients and healthy controls, evaluate the fulfillment of diagnostic criteria in seropositive cases, compare characteristics and outcomes between POMS and MOGAD, and identify clinical features associated with final diagnosis.
ANNALS OF NEUROLOGY
(2023)
Article
Clinical Neurology
Lauren B. Krupp, Emmanuelle Waubant, Michael Waltz, T. Charles Casper, Anita Belman, Yolanda Wheeler, Jayne Ness, Jennifer Graves, Mark Gorman, Leslie Benson, Soe Mar, Manu Goyal, Teri Schreiner, Bianca Weinstock-Guttman, Moses Rodriguez, Jan-Mendelt Tillema, Timothy Lotze, Greg Aaen, Mary Rensel, John Rose, Tanuja Chitinis, Allan George, Leigh E. Charvet
Summary: The cognitive differences between pediatric and adult multiple sclerosis (MS) are not well understood. This study compared cognitive performances in pediatric MS, adult MS, and pediatric healthy controls, and found that pediatric MS patients perform better than adults with MS on cognitive screens.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Neurosciences
Alexander Bartnik, Tom A. Fuchs, Kira Ashton, Amy Kuceyeski, Xian Li, Matthew Mallory, Devon Oship, Niels Bergsland, Deepa Ramasamy, Dejan Jakimovski, Ralph H. B. Benedict, Bianca Weinstock-Guttman, Robert Zivadinov, Michael G. Dwyer
Summary: This study investigated how the brain's functional organization changes over time with regard to structural damage, using multiple sclerosis as a model. It found that higher-order networks are more likely to experience changes in functional connectivity in response to structural damage compared to lower-order sensory networks.
Correction
Clinical Neurology
Penny Pennington, Bianca Weinstock-Guttman, Channa Kolb, Dejan Jakimovski, Katherine Sacca, Ralph H. B. Benedict, Svetlana Eckert, Marc Stecker, Alexis Lizarraga, Michael G. Dwyer, Carol B. Schumacher, Niels Bergsland, Patricia Picco, Evanthia Bernitsas, Rana Zabad, Gabriel Pardo, Donald Negroski, Martin Belkin, David Hojnacki, Robert Zivadinov
JOURNAL OF NEUROLOGY
(2023)
Article
Neurosciences
Ibrahim Abdollahpour, Yahya Salimi, Saharnaz Nedjat, Maryam Nazemipour, Mohammad Ali Mansournia, Bianca Weinstock-Guttman
Summary: The study found that there is an additive interaction between Dietary Inflammatory Index (DII) and drug abuse, gender, and history of depression in multiple sclerosis (MS). However, there is no evidence of multiplicative interaction between DII and other risk factors of MS.
NUTRITIONAL NEUROSCIENCE
(2023)
Article
Immunology
Dejan Jakimovski, Svetlana P. Eckert, Omid Mirmosayyeb, Sangharsha Thapa, Penny Pennington, David Hojnacki, Bianca Weinstock-Guttman
Summary: This study aimed to determine the real-world efficacy of tixagevimab and cilgavimab (Evusheld (TM)) in preventing breakthrough COVID-19 infections in immunosuppressed persons with neuroinflammatory diseases (pwNID). The results showed that pwNID treated with tixagevimab and cilgavimab had a significantly lower rate of COVID-19 infections and milder severity compared to the control group.
Article
Medicine, General & Internal
Nicholas Young, Robert Zivadinov, Michael G. Dwyer, Niels Bergsland, Bianca Weinstock-Guttman, Dejan Jakimovski
Summary: This study found that people with multiple sclerosis (pwMS) have fewer retinal blood vessels compared to healthy controls (HCs). Over time, pwMS experience a decrease in retinal vessel number while HCs experience an increase. Furthermore, there is a correlation between lower RNFL thickness and fewer retinal vessel number and smaller diameter in pwMS.
Article
Clinical Neurology
Jack A. Reeves, Zachary Weinstock, Robert Zivadinov, Michael G. Dwyer, Niels Bergsland, Fahad Salman, Ferdinand Schweser, Bianca Weinstock-Guttman, Ralph H. B. Benedict, Dejan Jakimovski
Summary: This study found that patients with relapsing-remitting multiple sclerosis (pwRRMS) who experienced relapse had higher prevalence of paramagnetic rim lesions (PRL) and worse cognitive recovery compared to stable controls.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Mary K. Horton, Joan E. Shim, Amelia Wallace, Jennifer S. Graves, Gregory Aaen, Benjamin Greenberg, Soe Mar, Yolanda Wheeler, Bianca Weinstock-Guttman, Amy Waldman, Teri Schreiner, Moses Rodriguez, Jan-Mendelt Tillema, Tanuja Chitnis, Lauren Krupp, T. Charles Casper, Mary Rensel, Janace Hart, Hong L. Quach, Diana L. Quach, Catherine Schaefer, Emmanuelle Waubant, Lisa F. Barcellos
Summary: Rare genetic variants play an important role in pediatric-onset multiple sclerosis (POMS). Specifically, genes associated with adult-onset MS risk (PRF1, PRKRA, NLRP8, and HDAC7) and 52 major histocompatibility complex (MHC) genes are also associated with POMS. These findings highlight the benefits of investigating rare genetic variation in complex diseases.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Vikram Bhise, Michael Waltz, T. Charles Casper, Gregory Aaen, Leslie Benson, Tanuja Chitnis, Mark Gorman, Manu S. Goyal, Yolanda Wheeler, Timothy Lotze, Soe Mar, Mary Rensel, Aaron Abrams, Moses Rodriguez, John Rose, Teri Schreiner, Nikita Shukla, Emmanuelle Waubant, Bianca Weinstock-Guttman, Jayne Ness, Lauren Krupp, Jan Mendelt-Tillema
Summary: In this study, we aimed to characterize a US cohort of children with incidental MRI findings suspect for demyelination and identify predictors of clinical and radiologic outcomes. The results showed that one-third of the patients had a clinical attack and three-quarters developed new MRI activity during a mean follow-up time of 3.7 years. Sex, presence of infratentorial lesions, T1 hypointense lesions, juxtacortical lesion count, and callosal lesions were found to be predictors of disease progression. Interestingly, T1 hypointense and infratentorial lesions, typically associated with worse outcomes, were predictive of delayed disease progression on imaging in subgroup analysis. Additionally, currently utilized diagnostic criteria did not provide statistically significant benefit in risk stratification, highlighting the need for further study.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Caila B. Vaughn, Katelyn S. Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman
Summary: A large retrospective study found that patient-reported limitations in physical and mental symptoms can predict future disability worsening in multiple sclerosis (MS) patients treated with intramuscular interferon-beta medication. The study also identified lower extremities limitations and fatigue as the most predictive factors for disability worsening.
NEURODEGENERATIVE DISEASE MANAGEMENT
(2023)
Article
Clinical Neurology
Michael G. Jaworski, John K. Gillies, Margaret Youngs, Curtis Wojcik, Celeste Santivasci, Dejan Jakimovski, Niels Bergsland, Bianca Weinstock-Guttman, Ralph H. B. Benedict
Summary: This study examined the neuropsychological measures of 198 people with multiple sclerosis (PwMS) and found that work-disabled PwMS performed the worst in terms of employment, while employed PwMS performed similarly to healthy volunteers. The Processing Speed Test (PST) and Symbol-Digit Modalities Test (SDMT) were identified as predictors of job deterioration in PwMS. These tests can serve as screening tools to identify PwMS at high risk of unemployment.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Dejan Jakimovski, Taylor R. Wicks, Niels Bergsland, Michael G. Dwyer, Bianca Weinstock-Guttman, Robert Zivadinov
Summary: This study found that patient-reported outcomes (PROs) are associated with concurrent and future impairments in persons with multiple sclerosis (pwMS). The structural and pathological relationships with PROs in pwMS have not been elucidated.
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE
(2023)
